Medicinova
Clinical trials sponsored by Medicinova, explained in plain language.
-
Could ibudilast be a Game-Changer for ALS patients?
Disease control OngoingThis study tests whether the drug ibudilast (MN-166) can slow the progression of ALS, a severe nerve disease that weakens muscles over time. About 234 adults with early-stage ALS will receive either ibudilast or a placebo for 12 months, followed by an open-label phase where every…
Phase: PHASE2, PHASE3 • Sponsor: MediciNova • Aim: Disease control
Last updated May 17, 2026 11:39 UTC
-
New pill aims to tackle fatty liver, diabetes, and high cholesterol in one go
Disease control OngoingThis phase 2 study tests an experimental drug called MN-001 (tipelukast) in 40 adults with non-alcoholic fatty liver disease, type 2 diabetes, and high triglycerides. Participants take either the drug or a placebo daily for 24 weeks. The main goals are to see if the drug reduces …
Phase: PHASE2 • Sponsor: MediciNova • Aim: Disease control
Last updated May 11, 2026 20:38 UTC